Holding Company Gives Eisai Presence, Options In China
This article was originally published in PharmAsia News
Eisai’s establishment of a new holding company for its operations in China marks another step in the building up of its activities in this key market and could facilitate potential acquisitions.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.